Advertisement
An audio Web cast of the Company's presentations will be available bygoing to the investor relations section of NeurogesX' Web site atwww.neurogesx.com. A replay of the presentation will be available for 15days.
Advertisement
About NeurogesX, Inc.
NeurogesX (Nasdaq: NGSX) is a biopharmaceutical company focused ondeveloping novel pain management therapies. Its initial focus is on chronicperipheral neuropathic pain, including postherpetic neuralgia (PHN), painfulHIV-distal sensory polyneuropathy (HIV-DSP) and painful diabetic neuropathy.NeurogesX' late stage product portfolio is led by its product candidateNGX-4010, a dermal patch designed to manage pain associated with peripheralneuropathic pain conditions, that the company believes offers significantadvantages over other pain therapies. Three Phase 3 clinical trials withNGX-4010 have been completed and have met their primary endpoints, two in PHNand one in painful HIV-DSP.
Safe Harbor Statement
This press release contains forward-looking statements for purposes of thePrivate Securities Litigation Reform Act of 1995 (the "Act"). NeurogesXdisclaims any intent or obligation to update these forward-looking statements,and claims the protection of the Safe Harbor for forward-looking statementscontained in the Act. Examples of such statements include, but are notlimited to, the timing of presentations by NeurogesX and the expected benefitsof NeurogesX' potential products, including its lead product candidateNGX-4010. Such statements are based on management's current expectations, butactual results may differ materially due to various risks and uncertainties,including, but not limited to, past results of clinical trials may not beindicative of future clinical trials results; NeurogesX' product candidate mayhave unexpected adverse side effects or inadequate therapeutic efficacy;positive results in clinical trials may not be sufficient to obtain FDA orEuropean regulatory approval; physician or patient reluctance to use NGX-4010,if approved, or the inability of physicians to obtain sufficient reimbursementfor such procedures; potential alternative therapies; maintaining adequatepatent or trade secret protection without violating the intellectual propertyrights of others; and other difficulties or delays in clinical development,obtaining regulatory approval, market acceptance and commercialization ofNGX-4010 and the advantages of NGX-4010 over other pain therapies. Forfurther information regarding these and other risks related to NeurogesX'business, investors should consult NeurogesX' filings with the Securities andExchange Commission.Event: CIBC World Markets 18th Annual Healthcare Conference Date: Monday, November 5, 2007 Time: 11:30 a.m. ET Place: The Waldorf-Astoria Hotel, New York Event: Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference Date: Tuesday, November 6, 2007 Time: 10:55 a.m. ET Place: New York Palace Hotel, New York
SOURCE NeurogesX, Inc.
